Ethical issues aside, this is a powerful addition to an already strong dataset on Covid-driven brain damage affecting cognition & memory. Given new (re)infections remain common, this work together with the Hampshire et al NEJM paper showing drop in IQ (summarized here

Looking forward to contributing to this area. Tomorrow at 14:55 in the Madrid auditorium, I'll be discussing our latest work on predicting endocrine toxicities following immunotherapy. #ESMO24

Air purifiers in Finnish daycare reduced children's illnesses by 18% in a carefully controlled study. This implies huge potential for better public health and cost savings from sick leaves, with a simple intervention against airborne infections. https://t.co/7F3KfB9Whw

Longitudinal Analysis Over Decades Reveals the Development and Immune Implications of Type I Interferon Autoantibodies in an Aging Population https://t.co/skNvjo73k3 #medRxiv

1/ Infections in human newborns: severe and frequent, due to age-specific vulnerability. Can this be reconciled with the immense interindividual variability of clinical outcome observed for any neonatal infection? Find out @ Cellular Immunology 👇 https://t.co/XKuBjrPfzV

Using a genetic approach (Mendelian randomization) cannabis use is not causally associated with risk of coronary artery disease or ischeamic stroke ! well done @roxanedelaharpe @zkutalik

Our study led by @somijemmacho examines a wide range of factors for predicting recurrent CAD events among pts with CAD. To our surprise, the top predictor was a CAD polygenic risk score. https://t.co/VD03nWwFLq @ESC_Journals [1/12]

1/ We are excited to share our report in @JExpMed showing that about 40% of cases of #WestNilevirus (#WNV) encephalitis are due to pre-existing auto-Abs neutralizing type I IFNs, making WNV encephalitis the best understood human infectious disease ( https://t.co/lqug2qZOMT).

Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients https://t.co/8d0W9tmCet Important discovery by @esiborghe & @casanova_lab 👏

@RegeneronDNA new preprint on the sequencing and analysis of 1M WES coming to you soon via a variant allele frequency browser. This goes far beyond @1000genomes (2.5k WGS), @dgmacarthur EXAC (60k WES) or @gnomad_project (125k exomes + 15k WGS) https://t.co/JywzusGaEg

This is crazy. And just how far above the 1982-2023 sea surface temperature average for the North Atlantic is the year 2023? Data: https://t.co/RxO8s5Y85O

New: Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years by Isabella Schoepf @unibern@UniBasel_en and colleagues https://t.co/z4bNTHTdHF #OpenAccess

The @bdsc_UNILCHUV has an open tenure-track faculty position in AI/ML for biomedicine. This is an amazing opportunity to work in a truly interdisciplinary environment, interacting with scientists and clinicians at the @CHUVLausanne and @unil. Please RT. https://t.co/7I88hk7QZs

Our latest research on the combined impact of genetics and infection on the risk of cardiovascular disease https://t.co/7UVrMRtR5d @epflSV @CHUVLausanne

Great work by Roxane & Christian on an important issue in clinical practice! @DptMedecineCHUV @CHUVLausanne Combining European and U.S. risk prediction models with polygenic risk scores to refine cardiovascular prevention: the CoLaus|PsyCoLaus Study

📢📢new pre-print out!!! With @jacquesfellay @precision_chuv we developed a #PRS combining multiple cardiac risk factors to predict the risk of sudden cardiac arrest in patients affected by coronary artery disease

Finally online at the Journal of Immunology: A Baseline Cellular Antiviral State Is Maintained by cGAS and Its Most Frequent Naturally Occurring Variant rs610913 by @JuliaKaz3 et al. https://t.co/Pc7Ev7GxlQ 1/4

Excited to share our @American_Heart Scientific Statement on Polygenic Risk Scores for Cardiovascular Disease! https://t.co/tS840STLmb @CircAHA @DrJackOSullivan @sridharan_r_ C. Marquez-Luna @JasmineLuzum @damrauer @euanashley @chrisodmd

What's the role of host genomics in #COVID19 occurrence and outcomes? Public health implications. Register TODAY to attend our October 6 webinar with @casanova_lab and @jacquesfellay. https://t.co/myNJHmyOvm

We've learned a lot over the past two years about the genetic architecture of the human response to SARS-CoV-2. Read our review in @ejhg_journal - with @cthorball @ClaireRedin https://t.co/dbMERTPRt9